Stomach bacterium H. pylori linked to metabolic syndrome in large Nanjing study

A common stomach bacterium that infects roughly four billion people worldwide may be doing more than causing ulcers. A new study from Nanjing, China, reports that adults carrying Helicobacter pylori were significantly more likely to have metabolic syndrome, the dangerous cluster of abdominal obesity, high blood sugar, elevated blood pressure, and abnormal cholesterol that sharply raises the risk of heart disease and type 2 diabetes. The research, published in BMC Infectious Diseases, adds a provocative new piece to one of the most debated puzzles in metabolic medicine: whether a chronic bacterial infection quietly living in the stomach lining can tip the body toward metabolic breakdown.

The findings come at a moment when scientists are increasingly recognizing that microbes do not stay confined to the gut lumen. Over the past two decades, researchers have documented that chronic infections and microbial imbalances can fuel systemic inflammation, disrupt insulin signaling, and alter lipid metabolism. H. pylori, a spiral-shaped Gram-negative bacterium that colonizes the gastric epithelium of an estimated half the global population, has long been suspected of playing such a role. It survives the stomach’s acidic environment by producing urease, an enzyme that neutralizes acid and allows the organism to burrow into the protective mucus layer. Once established, it can persist for decades, often without symptoms, while triggering a low-grade inflammatory response that some studies have linked to cardiovascular risk, insulin resistance, and altered blood sugar control.

To test whether this chronic colonization is actually associated with metabolic syndrome, a team led by Ruolin Peng and Haocheng Wang of the Department of Gastroenterology at Nanjing First Hospital analyzed data from 5,218 adults who underwent routine health checkups at the hospital’s Physical Examination Center between April 2024 and April 2025. For each participant, the researchers collected general demographic information, H. pylori infection status, anthropometric measurements including waist circumference and body mass index, and laboratory results covering fasting glucose, lipid panels, and blood pressure. Metabolic syndrome was diagnosed according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China, 2020 edition, which define the condition as a cluster of central obesity plus two or more additional metabolic abnormalities.

The results were striking. The overall H. pylori positivity rate in this health check-up population was 39.8 percent, consistent with the moderate prevalence seen across much of China. But when the researchers stratified participants by infection status, a clear pattern emerged. Metabolic syndrome was present in 8.6 percent of the H. pylori-positive group compared with just 5.4 percent of the H. pylori-negative group, a difference that was highly statistically significant. In other words, adults carrying the bacterium were roughly 60 percent more likely to meet the diagnostic criteria for metabolic syndrome than adults free of the infection.

When the team applied logistic regression models to control for potential confounders, the association held firm. After adjustment for age and sex, H. pylori infection was associated with significantly higher odds of metabolic syndrome, with an odds ratio of 1.85 and a 95 percent confidence interval of 1.48 to 2.31. This means that even after accounting for the two most obvious demographic differences between infected and uninfected adults, carrying the bacterium nearly doubled the likelihood of having metabolic syndrome in this population. The strength and consistency of this estimate across models suggests the association is not easily explained by age or sex differences alone.

Yet the story becomes more complicated when the researchers drilled down into the individual components of metabolic syndrome. In exploratory analyses restricted to participants who already had metabolic syndrome, the H. pylori-positive group was younger and contained a markedly lower proportion of men than the H. pylori-negative group, with men making up 43.3 percent of the infected group versus 92.9 percent of the uninfected group. This dramatic demographic imbalance suggests that the bacterium may interact differently with metabolic risk depending on who carries it, and it underscores why the researchers adjusted so carefully for age, sex, and body mass index in their component-level models.

Among participants with metabolic syndrome, the prevalence of hyperglycemia, or elevated fasting blood sugar, was significantly higher in the H. pylori-negative group than in the H. pylori-positive group, at 37.6 percent versus 22.5 percent. This counterintuitive finding suggests that among people who already have metabolic syndrome, those carrying the bacterium were actually less likely to show high blood sugar than those without it. However, when the researchers adjusted for age, sex, and body mass index, no statistically significant associations remained between H. pylori infection and any individual metabolic component, including abdominal obesity, elevated blood pressure, hyperglycemia, or dyslipidemia. The estimate for hyperglycemia shifted from an odds ratio of 0.48 to 0.63 after adjustment for age, indicating that some of the apparent protective effect was attributable to demographic differences rather than the bacterium itself.

The researchers are careful to emphasize what their study cannot prove. Because the design is cross-sectional, capturing a single moment in time, it cannot establish whether H. pylori infection precedes metabolic syndrome or whether people with metabolic syndrome are somehow more susceptible to the infection. The authors also note the potential for residual confounding from factors not measured in the health check-up data, as well as selection bias from studying a population that voluntarily undergoes health checkups. These limitations mean the findings do not establish temporality or causality, and the authors explicitly state that their results should not be interpreted as proof that eradicating H. pylori would prevent metabolic syndrome.

Still, the study’s technical approach and sample size give the association considerable weight. By using a series of logistic regression models with different covariate adjustments, the researchers were able to test how robust the association was to different assumptions about confounding. The fact that the odds ratio for metabolic syndrome remained stable and statistically significant across models, while the component-level associations dissolved after adjustment, tells a coherent statistical story. It suggests that H. pylori may be associated with metabolic syndrome as a whole, but that the bacterium’s apparent relationship with any single component is too weak or too entangled with demographic factors to detect reliably in this sample.

The biological plausibility of a link between chronic gastric infection and metabolic dysfunction rests on several mechanisms that researchers have been exploring for years. Chronic H. pylori colonization triggers sustained release of inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6, which can interfere with insulin receptor signaling in muscle and liver tissue. The bacterium has also been shown to alter gastric hormones, including ghrelin and leptin, which regulate appetite and energy balance. Some studies suggest that eradication of H. pylori can change circulating lipid levels and body weight, though the evidence remains mixed. The Nanjing findings now add population-level epidemiological support to this mechanistic framework, suggesting that the bacterium’s chronic inflammatory footprint may indeed be associated with the systemic metabolic changes that define metabolic syndrome.

What happens next will depend on whether other populations show the same pattern. If longitudinal studies following adults over time confirm that H. pylori infection precedes the onset of metabolic syndrome, the case for a causal role would strengthen considerably. Clinical trials testing whether eradication of the bacterium reduces metabolic risk would provide the most definitive answer. For now, the Nanjing study offers a compelling snapshot: in a large health check-up population, a bacterium that half the world carries was associated with nearly double the odds of metabolic syndrome, even after accounting for age and sex. Whether that association reflects a genuine biological effect or an unmeasured confounder remains an open question, but the scale of the finding ensures it will not be easily dismissed.

Subject of Research: Association of Helicobacter pylori infection with metabolic syndrome and its components: a retrospective cross-sectional study based on a health check-up population in Nanjing

Article Title: Association of Helicobacter pylori infection with metabolic syndrome and its components: a retrospective cross-sectional study based on a health check-up population in Nanjing

Article References: Peng, R., Wang, H., Huang, Y., Ge, C., Ma, M., Li, K., Cai, Z., Pan, J., Li, J., Tang, H., & Liu, W. (2026). Association of Helicobacter pylori infection with metabolic syndrome and its components: a retrospective cross-sectional study based on a health check-up population in Nanjing. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14439-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14439-4

Keywords: Association, Helicobacter, pylori, infection, metabolic, syndrome, components, retrospective, cross-sectional, based, health, check-up